BACKGROUND

- Herpes zoster (HZ) caused by reactivation of varicella zoster virus (VZV) typically involves a dermatomal lesion and can result in complications such as postherpetic neuralgia. HZ risk increases with age likely due to age-related decline of immunity.

- At the time of this study start, Zoster Vaccine Live (ZVL), containing live-attenuated VZV was recommended in the US for adults 65 years and older (≥65 YOA). The efficacy of the ZVL in older age groups ranged from 51.3% to 74.6% at 4 and 180 days after vaccination.1 The efficacy of ZVL declines from 53.3% to 21.1% by years 7-11 post-vaccination, in adults ≥60 YOA.2

- The Advisory Committee on Immunization Practices (ACIP) recommends RZV for adults ≥50 YOA and has noted declining HZ occurrence with age likely due to age-related decline of immunity.3

- RZV includes 50 μg of MPL (3-decyolphloroglucinol), an adjuvant system.

METHODS

- Study design: Here, we present immunogenicity and safety of RZV up to 12 months post dose 2 in adults ≥65 YOA

- Study participants and demographics:

  - Study participants were randomized to receive RZV at dose 1 and dose 2, or placebo.
  - N=198 total participants; 197 RZV and 1 placebo at dose 1, and 195 RZV at dose 2.
  - Age groups: 50.0% in ≥60 YOA, 37.6% in ≥70 YOA and 18% in ≥80 YOA adults.
  - The efficacy of ZVL with age likely due to age-related decline of immunity.

- Safety and reactogenicity:

  - Table 2. Incidence of unsolicited adverse events (AEs), serious AEs (SAEs) and potential immune-mediated diseases (pIMDs) in vaccinated adults ≥65 YOA at end-of-study results of a phase III, group-matched clinical trial.

- CONCLUSIONS

  - HZV induced strong humoral and cellular immune responses at similar levels in all participants, whether they had been vaccinated with ZVL ≥5 years earlier or had never received ZVL.
  - No clinically significant differences were observed in the HZV reactogenicity and safety profile regardless of previous ZVL vaccination.

- References:


- For more information, visit: https://www.idweek.org/
Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched Clinical Trial

Authors and Presenter: Tomas Mrkvan, PhD; Laura Campora, MD; Grégory Catteau, MSc; Martine Douha, MSc; Katrijn Grupping, PhD; Caroline Hervé, PhD; George Kalema, PhD; Thomas C. Heineman, MD, PhD; Nicola P. Klein, MD, PhD; Himal Lal, MD; Lidia Oostvogels, MD; Anne Schuind, MD

Affiliations:
1. GSK, Wavre, Belgium;
2. Keyrus Biopharma, Waterloo, Belgium;
3. Halozyme Therapeutics, San Diego, California, US;
4. Kaiser Permanente Vaccine Study Center, Oakland, California, US;
6. CureVac AG, Tübingen, Germany;
7. GSK, Rockville, Maryland, US.

CONFLICT OF INTEREST

AS, HL, TM, TCH, LC, LO, CH, KG and MD are/were employees of the GSK group of companies. LO is employee of CureVac AG as of March 1st 2018 and is an inventor on a patent application related to the vaccine used in this study. HL is employee of Pfizer and receives salary and stock, as compensation from Pfizer Inc. AS, TM, TCH, HL and LC also hold/held shares in the GSK group of companies as part of their employee remuneration. GC is/was a board member in the GSK group of companies. GK and TCH are/were GSK consultants and received consultant fees. TCH is an inventor on a patent application related to the vaccine used in this study. NPK received research support from GSK group of companies during the conduct of this study, as well as grants from Sanofi Pasteur, Merck& Co, Pfizer Inc., Protein Science (now S-P), MedImmune and Dynavax for work outside of this study.

ACKNOWLEDGEMENTS:

The authors would like to thank all study participants and all staff members at the study sites as well as GSK study staff for their contribution to the study.

Writing and editorial support were provided by Mara Naghi and Divya Kesters (XPE Pharma & Science, for GSK).